IRIS
LEONETTI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.305
EU - Europa 1.233
AS - Asia 647
SA - Sud America 90
AF - Africa 23
OC - Oceania 3
Totale 3.301
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.285
IT - Italia 413
SG - Singapore 355
IE - Irlanda 262
SE - Svezia 237
CN - Cina 161
BR - Brasile 76
DE - Germania 66
RU - Federazione Russa 35
AT - Austria 33
FR - Francia 32
FI - Finlandia 31
IN - India 27
NL - Olanda 25
ID - Indonesia 24
GB - Regno Unito 20
CI - Costa d'Avorio 18
BD - Bangladesh 17
CZ - Repubblica Ceca 16
BE - Belgio 15
IR - Iran 11
TR - Turchia 11
CA - Canada 10
HK - Hong Kong 9
PK - Pakistan 9
LT - Lituania 7
AR - Argentina 6
CH - Svizzera 6
LU - Lussemburgo 6
MX - Messico 5
UA - Ucraina 5
UZ - Uzbekistan 4
VN - Vietnam 4
AU - Australia 3
BG - Bulgaria 3
CO - Colombia 3
IQ - Iraq 3
MD - Moldavia 3
NO - Norvegia 3
DK - Danimarca 2
DO - Repubblica Dominicana 2
EG - Egitto 2
ES - Italia 2
HR - Croazia 2
KR - Corea 2
PE - Perù 2
PL - Polonia 2
VE - Venezuela 2
ZA - Sudafrica 2
AL - Albania 1
AZ - Azerbaigian 1
BS - Bahamas 1
BY - Bielorussia 1
CR - Costa Rica 1
EC - Ecuador 1
EE - Estonia 1
JM - Giamaica 1
JP - Giappone 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LV - Lettonia 1
MA - Marocco 1
MK - Macedonia 1
MY - Malesia 1
NP - Nepal 1
PH - Filippine 1
QA - Qatar 1
RO - Romania 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 3.301
Salva come PNG Salva come JPEG
Città #
Chandler 284
Dublin 259
Singapore 230
Santa Clara 170
Parma 100
Ashburn 98
Boardman 94
Shanghai 84
New York 65
Bologna 40
Princeton 38
Milan 35
Chicago 28
Helsinki 26
Vienna 26
Ann Arbor 24
Marseille 24
Moscow 22
Jakarta 21
Verona 19
Abidjan 18
Des Moines 18
Rome 18
Nuremberg 17
Bremen 16
Los Angeles 15
Munich 13
West Jordan 12
Amsterdam 11
Modena 11
Reggio Emilia 11
Brno 10
Dallas 10
Fremont 10
London 10
São Paulo 10
Beijing 9
Brussels 9
Sorbolo 9
Trento 9
Wilmington 9
Frankfurt am Main 7
Istanbul 7
Pune 7
Toronto 7
Council Bluffs 6
Florence 6
Hong Kong 6
Houston 6
Louvain-la-Neuve 6
North Bergen 6
Bolzano 5
Cavriago 5
Lahore 5
Verdellino 5
Ardea 4
Assago 4
Dong Ket 4
Kochi 4
Kolkata 4
Olomouc 4
Phoenix 4
Tashkent 4
Wayne 4
Aachen 3
Belo Horizonte 3
Borås 3
Brescia 3
Dearborn 3
Fairfield 3
Fortaleza 3
Genoa 3
Jinan 3
Kyiv 3
Lonato 3
Melbourne 3
Norwalk 3
Piacenza 3
Salvador 3
San Giuliano Milanese 3
Scandiano 3
Sofia 3
Tehran 3
Zhengzhou 3
Atlanta 2
Ayr 2
Bhubaneswar 2
Brasília 2
Cairo 2
Campinas 2
Central 2
Chisinau 2
Clifton 2
Contagem 2
Créteil 2
Curitiba 2
Daejeon 2
Dhaka 2
Dietikon 2
Falls Church 2
Totale 2.154
Salva come PNG Salva come JPEG
Nome #
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 102
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 94
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 88
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 88
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 87
The role of miRNA-221 and miRNA-126 in patients with benign metastasizing leiomyoma of the lung: an overview with new interesting scenarios 87
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY 80
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 78
Monitoring cfDNA in plasma and in other liquid biopsies of advanced EGFR mutated NSCLC patients: A pilot study and a review of the literature 74
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 74
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 73
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 70
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 67
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 66
227P Sexual dimorphism in immune profile of early and advanced NSCLC 66
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 65
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy 64
Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial 64
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients 63
Osimertinib in CNS-progressive EGFR-mutant lung cancer: do we need to detect T790M? 62
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 61
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The practice study 60
Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC? 60
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 59
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 58
A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients? 58
Relationship Between the Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) and Lung Adenocarcinoma Patterns: New Possible Insights 57
Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review 56
COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors 52
Dynamic evaluation of circulating mirna profile in egfr‐ mutated nsclc patients treated with egfr‐tkis 52
Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study 51
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 50
Everolimus in the management of metastatic renal cell carcinoma: An evidence-based review of its place in therapy 50
Small cell lung cancer: Novel treatments beyond immunotherapy 48
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 48
Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer? 48
Letter comments on: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression 48
Takotsubo syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab plus axitinib 47
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 47
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 44
Adjuvant tyrosine kinase inhibitors for renal cell carcinoma? No, thank you (at least for the present) 44
Radiotherapy for the treatment of distant nodes metastases from oligometastatic urothelial cancer: A retrospective case series 43
Primary Retroperitoneal Cystoadenocarcinoma: A Systematic Review 39
Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib 38
Can we optimize the selection of patients with lung cancer suitable for EGFR+MET double inhibition? 37
“Finding NEMO” in NRAS-mutant melanoma: a step towards a sequential strategy? 37
Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma 36
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer 33
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 31
Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review 31
Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary? 31
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 29
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer 29
The role of the microbiome in cancer and therapy efficacy: Focus on lung cancer 29
Thirty-day mortality in hospitalised patients with lung cancer: incidence and predictors 28
5P Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC 28
Potential ROle of hypovitaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): a prospective observational study. 27
Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC 27
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers 27
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators 26
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study 26
2125P Potential ROle of hypoVItaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): A prospective observational study 25
The link between calcitriol and anticancer immunotherapy: Vitamin D as the possible balance between inflammation and autoimmunity in the immune-checkpoint blockade 25
Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review 23
7P STK11 and Galectin-3 tissue expression entails a prognostic signature in immunotherapy treated NSCLC patients 22
Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysis 20
P57.08 High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC 19
Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results 16
EP.15B.05 Predictors of 30-Day Mortality after Systemic Therapy in Hospitalized Lung Cancer Patients: A Retrospective Single-Center Observational Study 15
Totale 3.407
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.235
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.235
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203 0 0 0 0 0 0 0 0 0 3 0 0
2020/202165 0 0 0 8 5 8 5 8 10 5 2 14
2021/2022276 9 4 33 19 2 6 77 15 4 0 27 80
2022/20231.046 111 126 43 87 112 112 20 57 305 3 48 22
2023/2024754 37 49 34 26 74 128 85 35 53 56 60 117
2024/20251.254 63 125 155 149 163 184 137 93 185 0 0 0
Totale 3.407